Virtual Library
Start Your Search
- Virtual Library Home
- IASLC Library
- Explore Event
-
WCLC 2020
2020 World Conference on Lung Cancer
Conference Program for the 2020 World Conference on Lung Cancer
Presentation Date(s):- January 28 - 31, 2021
- Total Presentations: 1597
To review abstracts of the presentations below, narrow down your search by using the Filter options below, and then select the session listing of your choice. Click the "+" for a presentation to expand & view the corresponding Abstract details.
Presentations will be available 24 hours after their live presentation time
-
+
FP04 - Locoregional and Oligometastatic Disease
- Type: Posters (Featured)
- Track: Locoregional and Oligometastatic Disease
- Presentations: 5
- Coordinates: 1/28/2021, 00:00 - 00:00, ePoster Hall
-
+
FP04.04 - EGFR Mutations Predict Superior Survival of NSCLC Patients with Oligometastatic Disease Treated with Local Consolidative Therapy
00:00 - 00:00 | Presenter: Ahsan Farooqi
- Abstract
Loading...
-
+
FP07 - Pathology
- Type: Posters (Featured)
- Track: Pathology, Molecular Pathology and Diagnostic Biomarkers
- Presentations: 17
- Coordinates: 1/28/2021, 00:00 - 00:00, ePoster Hall
-
+
FP07.10 - Circulating Tumor DNA Analysis in NSCLC with MET exon 14 Skipping Alterations
00:00 - 00:00 | Presenter: Xiuning Le
- Abstract
Loading...
-
+
FP14 - Targeted Therapy - Clinically Focused
- Type: Posters (Featured)
- Track: Targeted Therapy - Clinically Focused
- Presentations: 16
- Coordinates: 1/28/2021, 00:00 - 00:00, ePoster Hall
-
+
FP14.09 - Tepotinib Safety in MET Exon 14 (METex14) Skipping NSCLC: Updated Results from the VISION Trial
00:00 - 00:00 | Presenter: Rémi Veillon
- Abstract
Loading...
-
+
P76 - Targeted Therapy - Clinically Focused - EGFR
- Type: Posters
- Track: Targeted Therapy - Clinically Focused
- Presentations: 98
- Coordinates: 1/28/2021, 00:00 - 00:00, ePoster Hall
-
+
P76.03 - Efficacy and Safety of Capmatinib Plus Nivolumab in Pretreated Patients with EGFR Wild-Type Non–Small Cell Lung Cancer
00:00 - 00:00 | Presenter: Enriqueta Felip
- Abstract
Loading... -
+
P76.27 - ORCHARD: A Biomarker-Directed Phase 2 Platform Study in pts with Advanced EGFRm NSCLC Progressing on First-Line Osimertinib
00:00 - 00:00 | Presenter: Byoung Chul Cho
- Abstract
Loading... -
+
P76.62 - RAMOSE: An Open-Label Randomized Phase II Study of Osimertinib with or without Ramucirumab in TKI-Naïve EGFR-Mutant Metastatic NSCLC
00:00 - 00:00 | Presenter: Andreas N Saltos
- Abstract
Loading...
-
+
P85 - Targeted Therapy - Clinically Focused - MET
- Type: Posters
- Track: Targeted Therapy - Clinically Focused
- Presentations: 7
- Coordinates: 1/28/2021, 00:00 - 00:00, ePoster Hall
-
+
P85.01 - Activity of Tepotinib in Brain Metastases (BM): Preclinical and Clinical Data in MET Exon 14 (METex14) Skipping NSCLC
00:00 - 00:00 | Presenter: Julien Mazieres
- Abstract
Loading...
-
+
MA11 - Expanding Targetable Genetic Alterations in NSCLC
- Type: Mini Oral
- Track: Targeted Therapy - Clinically Focused
- Presentations: 12
- Coordinates: 1/31/2021, 14:15 - 15:15, Scientific Program Auditorium
-
+
MA11.04 - Updated Efficacy, Safety and Dosing Management of Poziotinib in Previously Treated EGFR and HER2 Exon 20 NSCLC Patients
14:20 - 14:25 | Presenter: Robin Cornelissen
- Abstract
Loading... -
+
MA11.05 - Tepotinib in Patients with MET exon 14 (METex14) Skipping Advanced NSCLC: Updated Efficacy Results from VISION Cohort A
14:25 - 14:30 | Presenter: Paul K. Paik
- Abstract
Loading...
-
+
MA13 - Tumor Biology: Focus on EGFR Mutation, DNA Repair and Tumor Microenvironment
- Type: Mini Oral
- Track: Tumor Biology and Systems Biology - Basic and Translational Science
- Presentations: 10
- Coordinates: 1/31/2021, 16:45 - 17:45, Scientific Program Auditorium
-
+
MA13.07 - Structural Classification of Atypical EGFR Mutations Identifies 4 Major Subgroups with Distinct Patterns of Drug Sensitivity
17:20 - 17:25 | Presenter: Jacqulyne Ponville Robichaux
- Abstract
Loading...